A Phase 2 trial of YTX-7739 in patients with Parkinson's disease
Latest Information Update: 02 Jan 2023
At a glance
- Drugs YTX 7739 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Kineta; Yumanity Therapeutics
- 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
- 24 Nov 2021 New trial record